The rate of cell growth is regulated by purine biosynthesis via ATP production and G(1) to S phase transition.
We recently showed that an increased supply of purine nucleotides increased the growth rate of cultured fibroblasts. To understand the mechanism of the growth rate regulation, CHO K1 (a wild type of Chinese hamster ovary fibroblast cell line) and CHO ade (-)A (a cell line deficient in amidophosphoribosyltransferase, a rate-limiting enzyme of the de novo pathway) were cultured under various conditions. Moreover, a defective de novo pathway in CHO ade (-)A cells was exogenously restored by 5-amino-4-imidazole-carboxamide riboside, a precursor of the de novo pathway. The following parameters were determined: the growth rate of CHO fibroblasts, the metabolic rate of the de novo pathway, the enzyme activities of amidophosphoribosyltransferase and hypoxanthine phosphoribosyltransferase, the content of intracellular nucleotides, and the duration of each cell-cycle phase. We concluded the following: (i) Purine de novo synthesis, rather than purine salvage synthesis or pyrimidine synthesis, limits the growth rate. (ii) Purine nucleotides are synthesized preferentially by the salvage pathway as long as hypoxanthine is available for energy conservation. (iii) The GTP content depends on the intracellular ATP content. (iv) Biosynthesis of purine nucleotides increases the growth rate mainly through ATP production and promotion of the G(1)/S transition.
Kondo
M
M
Otsuka Department of Molecular Nutrition, School of Medicine, The University of Tokushima, Tokushima 770-8503, Japan.
Yamaoka
T
T
Honda
S
S
Miwa
Y
Y
Katashima
R
R
Moritani
M
M
Yoshimoto
K
K
Hayashi
Y
Y
Itakura
M
M
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000582:Amidophosphoribosyltransferase / Q000235:genetics / Q000378:metabolism; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D016466:CHO Cells / Q000187:drug effects / Q000378:metabolism; D002453:Cell Cycle / Q000502:physiology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D006224:Cricetinae; D003412:Cricetulus; D003470:Culture Media; D016193:G1 Phase / Q000502:physiology*; D006160:Guanosine Triphosphate / Q000378:metabolism; D019271:Hypoxanthine / Q000378:metabolism / Q000494:pharmacology; D007041:Hypoxanthine Phosphoribosyltransferase / Q000378:metabolism; D009713:Nucleotidyltransferases / Q000378:metabolism; D011687:Purines / Q000096:biosynthesis* / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D012263:Ribonucleosides / Q000378:metabolism / Q000494:pharmacology; D016196:S Phase / Q000502:physiology*
D003470:Culture Media; D011687:Purines; D011743:Pyrimidines; D012263:Ribonucleosides; D019271:Hypoxanthine; D000620:Aminoimidazole Carboxamide; C011651:acadesine; D006160:Guanosine Triphosphate; D000255:Adenosine Triphosphate; D000582:Amidophosphoribosyltransferase; D007041:Hypoxanthine Phosphoribosyltransferase; D009713:Nucleotidyltransferases; C020658:glutamine-synthetase adenylyltransferase